6,763 Shares in Hologic, Inc. (NASDAQ:HOLX) Bought by Bryce Point Capital LLC

Bryce Point Capital LLC acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 6,763 shares of the medical equipment provider’s stock, valued at approximately $488,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Benson Investment Management Company Inc. purchased a new position in Hologic in the fourth quarter worth about $4,832,000. Principal Financial Group Inc. boosted its holdings in shares of Hologic by 0.6% in the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock worth $19,547,000 after purchasing an additional 1,606 shares during the period. Clean Yield Group increased its position in shares of Hologic by 18.9% during the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock valued at $3,291,000 after purchasing an additional 7,266 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock worth $2,344,000 after buying an additional 800 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after acquiring an additional 238,222 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HOLX has been the subject of a number of recent analyst reports. Morgan Stanley dropped their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Jefferies Financial Group started coverage on Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price for the company. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Citigroup dropped their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Stephens reiterated an “overweight” rating and issued a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Stock Down 1.3 %

Shares of NASDAQ HOLX opened at $60.86 on Friday. Hologic, Inc. has a 12-month low of $59.06 and a 12-month high of $84.67. The stock’s fifty day simple moving average is $64.30 and its two-hundred day simple moving average is $72.65. The stock has a market capitalization of $13.66 billion, a PE ratio of 19.20, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.